05.01.07
Optigenex, Inc., New York, NY, has signed an exclusive trademark licensing agreement for the territory of North America with RFI Ingredients, Blauvelt, NY, to market AC-11 in the health practitioner channel. The agreement will give RFI access to the AC-11 registered trademark and utilize the scientifically validated qualities of this unique compound. In third party pre-clinical and scientific studies, AC-11 has been shown to support the body’s natural ability to repair damage to DNA due to multiple causes, including harmful effects of UV radiation from exposure to the sun, stress, environmental pollution and other toxins. In addition, in separate third party studies AC-11 has been established as an inhibitor of pro-inflammatory agents and has demonstrated effectiveness as a natural immune stimulator and anti-tumor agent.